We are live on ! Find out more
BMRN icon

BioMarin Pharmaceuticals
BMRN

341 hedge funds and large institutions have $13.4B invested in BioMarin Pharmaceuticals in 2014 Q4 according to their latest regulatory filings, with 58 funds opening new positions, 108 increasing their positions, 133 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

115% more first-time investments, than exits

New positions opened: 58 | Existing positions closed: 27

97% more call options, than puts

Call options by funds: $116M | Put options by funds: $59M

25% more capital invested

Capital invested by funds: $10.7B → $13.4B (+$2.68B)

22% more funds holding in top 10

Funds holding in top 10: 9 → 11 (+2)

8% more funds holding

Funds holding: 316 → 341 (+25)

19% less repeat investments, than reductions

Existing positions increased: 108 | Existing positions reduced: 133

Holders
341
Holders Change
+25
Holders Change %
+7.91%
% of All Funds
9.09%
Holding in Top 10
11
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+22.22%
% of All Funds
0.29%
New
58
Increased
108
Reduced
133
Closed
27
Calls
$116M
Puts
$59M
Net Calls
+$57.3M
Net Calls Change
+$5.08M

Top Buyers

Rank Fund Capital Flow
1
Victory Capital Management
Victory Capital Management
Texas
+$120M
2
BBA
Baker Bros. Advisors
New York
+$112M
3
TCIM
TIAA CREF Investment Management
New York
+$104M
4
VAM
Visium Asset Management
New York
+$82.2M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$70.8M

Top Sellers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
-$108M
2
Wells Fargo
Wells Fargo
California
-$86.5M
3
AGA
Altrinsic Global Advisors
Connecticut
-$77.4M
4
Alkeon Capital Management
Alkeon Capital Management
New York
-$54.6M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
-$50M
Name Holding Trade Value Shares
Change 		Change in
Stake
ZCI
176
Zevenbergen Capital Investments
Washington
$2.18M +$2M +24,077 New
Nomura Asset Management
177
Nomura Asset Management
Japan
$2.17M -$27.4K -330 -1%
KSCM
178
Kamunting Street Capital Management
Florida
$2.15M -$283K -3,400 -13%
GA
179
Geneva Advisors
Illinois
$2.1M +$161K +1,935 +9%
BACM
180
Blue Arrow Capital Management
New York
$2.08M +$1.91M +22,959 New
CWM
181
Cabot Wealth Management
Massachusetts
$2.06M -$2.23M -26,773 -54%
BLM
182
Bennett Lawrence Management
New York
$2.03M +$1.87M +22,430 New
RFC
183
Russell Frank Company
Washington
$2.02M +$493K +5,931 +36%
FLAM
184
First Light Asset Management
Minnesota
$1.99M +$144K +1,737 +9%
WCA
185
Westover Capital Advisors
Delaware
$1.98M -$143K -1,724 -7%
SEI Investments
186
SEI Investments
Pennsylvania
$1.97M +$1.82M +21,831 New
BF
187
BOK Financial
Oklahoma
$1.93M -$1.09M -13,116 -38%
LS
188
Livforsakringsbolaget Skandia
Sweden
$1.84M – – –
SCM
189
Shelton Capital Management
Colorado
$1.81M -$6.99M -84,000 -81%
FRM
190
Fore Research & Management
New York
$1.81M -$2.49M -30,000 -60%
Mitsubishi UFJ Asset Management
191
Mitsubishi UFJ Asset Management
Japan
$1.81M -$216K -2,599 -12%
AC
192
Ascend Capital
California
$1.81M -$11.7M -140,650 -88%
Two Sigma Investments
193
Two Sigma Investments
New York
$1.8M +$1.66M +19,920 New
Janus Henderson Group
194
Janus Henderson Group
United Kingdom
$1.64M – – –
SF
195
Synovus Financial
Georgia
$1.58M -$74.8K -900 -5%
GT
196
Glenmede Trust
Pennsylvania
$1.55M +$92.3K +1,110 +7%
Principal Financial Group
197
Principal Financial Group
Iowa
$1.54M +$373K +4,490 +36%
ECP
198
Elk Creek Partners
Colorado
$1.52M +$1.4M +16,809 New
TAM
199
Tocqueville Asset Management
New York
$1.46M +$83.2K +1,000 +7%
CGI
200
Comgest Global Investors
France
$1.45M +$1.33M +16,000 New
6 7
8
9 10

BMRN Hedge Fund Activity: Q4 2014 in Review

341 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q4 2014, worth a combined $13.4B — up 25% from $10.7B a quarter earlier.

Buyers outnumbered sellers: 58 funds opened new BMRN positions and 27 closed out — a net gain of 31 holders — while 108 added to existing stakes and 133 trimmed.

The largest buyer was Victory Capital Management, opening a new position worth an estimated $120M. The largest seller was State Street, cutting an estimated $108M.

  • 341 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q4 2014, up from 316 in Q3 2014.
  • Funds reported $13.4B of BioMarin Pharmaceuticals stock for Q4 2014, up 25% quarter-over-quarter.
  • 58 funds opened new BioMarin Pharmaceuticals positions in Q4 2014 and 27 closed out, a net change of +31 holders.
  • The largest BioMarin Pharmaceuticals buyer in Q4 2014 was Victory Capital Management, an estimated $120M added.
  • The largest BioMarin Pharmaceuticals seller in Q4 2014 was State Street, an estimated $108M sold.

Based on aggregated 13F filings for Q4 2014.